Labcorp Q4 revenue $3.33B (+9.8% YoY); adj. EPS $3.45; FY2025 rev. midpoint ~$14.0B, adj. EPS $16.00

LABCORP HOLDINGS INC.

2024-FY EPS reported $8.84 revenue$13,008,900,000

Q4 revenue $3.33B (+9.8% YoY); diluted EPS $1.70 vs ($1.95); adjusted EPS $3.45 vs $3.30; free cash flow $665.1M vs $412.4M.
Full year 2024 revenue $13.01B (+7.0%); diluted EPS $8.84 vs $4.33; adjusted EPS $14.57 vs $13.56; free cash flow $1.10B vs $748.7M.
Diagnostics Labs segment Q4 revenue $2.59B (+10.2%); Biopharma Lab Services revenue $767.0M (+10.4%).
FY2025 guidance: revenue $13.88B-$14.05B (midpoint +7.4%), adjusted EPS $15.60-$16.40 (midpoint +9.8%), free cash flow $1.10B-$1.25B.
Board declared $0.72 quarterly dividend payable March 12, 2025; $839M spent on acquisitions in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.